Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Obalon Therapeutics (OBLN) Competitors

Obalon Therapeutics logo

OBLN vs. CERS, TCMD, NYXH, NVRO, DRTS, SKIN, CATX, BWAY, OSUR, and SGHT

Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Cerus (CERS), Tactile Systems Technology (TCMD), Nyxoah (NYXH), Nevro (NVRO), Alpha Tau Medical (DRTS), Beauty Health (SKIN), Perspective Therapeutics (CATX), BrainsWay (BWAY), OraSure Technologies (OSUR), and Sight Sciences (SGHT). These companies are all part of the "medical" sector.

Obalon Therapeutics vs.

Obalon Therapeutics (NASDAQ:OBLN) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.

Obalon Therapeutics has higher earnings, but lower revenue than Cerus.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Obalon Therapeutics$1.59M30.07-$12.33MN/AN/A
Cerus$185.14M1.31-$37.49M-$0.10-12.65

Cerus has a net margin of -11.60% compared to Obalon Therapeutics' net margin of -776.76%. Cerus' return on equity of -40.55% beat Obalon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Obalon Therapeutics-776.76% -161.38% -83.58%
Cerus -11.60%-40.55%-11.12%

Obalon Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Cerus received 324 more outperform votes than Obalon Therapeutics when rated by MarketBeat users. Likewise, 72.34% of users gave Cerus an outperform vote while only 46.42% of users gave Obalon Therapeutics an outperform vote.

CompanyUnderperformOutperform
Obalon TherapeuticsOutperform Votes
246
46.42%
Underperform Votes
284
53.58%
CerusOutperform Votes
570
72.34%
Underperform Votes
218
27.66%

18.6% of Obalon Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 8.1% of Obalon Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cerus has a consensus target price of $3.50, indicating a potential upside of 176.68%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Obalon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Obalon Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cerus
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cerus had 2 more articles in the media than Obalon Therapeutics. MarketBeat recorded 2 mentions for Cerus and 0 mentions for Obalon Therapeutics. Cerus' average media sentiment score of 0.94 beat Obalon Therapeutics' score of 0.00 indicating that Cerus is being referred to more favorably in the news media.

Company Overall Sentiment
Obalon Therapeutics Neutral
Cerus Positive

Summary

Cerus beats Obalon Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Obalon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBLN vs. The Competition

MetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$47.81M$4.41B$5.34B$8.46B
Dividend YieldN/A45.22%5.29%4.18%
P/E Ratio-3.5329.2826.8819.78
Price / Sales30.0772.30398.48138.40
Price / CashN/A51.0838.2534.64
Price / Book7.956.186.764.54
Net Income-$12.33M$66.90M$3.22B$247.85M

Obalon Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBLN
Obalon Therapeutics
N/A$4.77
+0.2%
N/A+2,431.9%$47.81M$1.59M-3.532
CERS
Cerus
2.9012 of 5 stars
$1.32
-0.8%
$3.50
+165.2%
-31.5%$252.33M$185.14M-12.00290Positive News
Gap Down
TCMD
Tactile Systems Technology
3.4704 of 5 stars
$10.40
flat
$16.00
+53.8%
-24.0%$241.78M$293.16M14.86980Positive News
NYXH
Nyxoah
2.6259 of 5 stars
$6.79
+7.9%
$14.50
+113.5%
-8.8%$231.27M$4.52M-3.63110Gap Up
High Trading Volume
NVRO
Nevro
0.189 of 5 stars
$5.85
+0.1%
$5.36
-8.3%
-37.7%$224.32M$408.52M-3.091,090News Coverage
DRTS
Alpha Tau Medical
1.9769 of 5 stars
$3.10
+11.1%
$8.00
+158.1%
+21.3%$218.18MN/A-7.2180News Coverage
Analyst Revision
Gap Up
High Trading Volume
SKIN
Beauty Health
0.2336 of 5 stars
$1.64
-5.7%
$1.42
-13.6%
-32.9%$217.93M$322.47M-3.901,030Trending News
Gap Down
CATX
Perspective Therapeutics
3.4096 of 5 stars
$2.73
+3.8%
$12.50
+357.9%
-84.0%$202.64M$1.43M0.0070
BWAY
BrainsWay
3.2766 of 5 stars
$10.65
+7.5%
$14.25
+33.8%
+97.2%$200.99M$43.46M106.51120News Coverage
Positive News
Analyst Revision
OSUR
OraSure Technologies
3.1621 of 5 stars
$2.63
+8.2%
$3.00
+14.1%
-42.9%$196.72M$161.63M17.53840
SGHT
Sight Sciences
3.0266 of 5 stars
$3.27
-7.9%
$3.92
+19.8%
-38.2%$183.52M$78.11M-3.21210Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:OBLN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners